Member Info for Sangijuelas1

The way all the posters whose investment is underwater come out to try and ramp up the price so they can offload their shares on to the next mug.

FDA approval would come at the end of a P3 although there are accelerated approval pathways if the circumstances are right.
This is basically trying to do the right thing for the patient by making an investigational drug available to them that could possibly help improve their condition.
The patient and their physician will have applied to be able to access Foralumab

Oh and I am filtering you for swearing and for investing in BRH

Maybe you need to read up on the FDA expanded access programme.
I will go with what the RNS states

So people here don't like being confronted with reality and facts. They want magical thinking instead.
Maybe more people are posting because they have been attracted by the news. Let's be frank. There's been no point even reading this board recently as all its about is people moaning about their Accustem shares.
I only checked in as I wondered why the price had ticked up.

No Starknight no apology. I will start again with a simple question.
Is the P2 MS trial for Primary Progressive or Secondary Progressive or for both types as the presentation just says Progressive MS?

Exactly I was just about to make the same point. The FDA don't approve drugs under the EA programme.
https://www.fda.gov/news-events/expanded-access/expanded-access-information-industry

You just see the words FDA approval and you go nuts without reading the whole sentence and knowing what it means.
Crikey if Forulamab was approved to treat MS the price would go up 10 times in a day.

I mean all you had to do was some basic research on your investment so that when an RNS comes through you can make sense of it.
And you haven't even done that, have you?

None of you have a clue what is going on here do you?
I'm a casual investor here as my main priorities are elsewhere.

You are confused Starknight. There is a P2 for MS scheduled in Q2. This is separate to that. That is why I am trying to find out if it is an additional indication to that planned with the P2

FDA approval for Compassionate use in 1 patient. What did you think it meant?

Does anyone know the answer to this? It's kind of relevant. Primary and secondary are 2 separate conditions with different pathologies.
The presentation says the P2 trial is for Progressive MS. Is it primary or secondary?

I think this will be specific to MS Nelson. I don't think the Covid data will have played a part. More the P1 data from the first MS trial that showed it was safe to use in humans.
The MS patient is being granted access to it for Compassionate use as the risks are likely to be less than the potential improvement in their condition for which there will be no viable alternatives

The planned P2 trial for MS is for primary progressive and this is an approval for Compassionate use in another indication that being Secondary Progressive MS

Ok thanks

Where are you getting the information that they are delayed due to Nasdaq listing?

Seems kinda rude not to partake

Mind if I do.

There's a video of it on the reports and presentations part of the website